Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Groupe Francais De Pneumo-Cancerologie
A multicenter phase II trial,prospective,randomized,open,non comparative
Age
65–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age \> 65
Comorbidities score, PS and frailty score according to table 1
No dementia, faecal or urinary incontinence, repeated falls
ADL = 0, IADL = 0-1
Life expectancy at least 12 weeks
Creatinin clearance \> = 30 ml/mn (according to Cockcrofts-Gault formula)
Competency to give written informed consent
Haematological functions as follows : neutrophiles count \> 1.5 x 109/l and platelets \> 100 x 109/l hemoglobin \> 9,5 g/dl - Hepatic function as follows : Bilirubin \< 1,25 LNS ASAT / ALAT \<5 x NAlcPh \<5 x N
PS \< 3
Histologically or cytologically confirmed NSCLC
Stage IV/IIIB4 (T4 with pleural effusion)
No prior chemotherapy
relapses of previous NSCLC treated by surgery or radiotherapy are eligible, if the target is measurable out of initial radiotherapy field and if cytological or histological proof
At least one measurable target lesion by RECIST guidelines
You may not be if
symptomatic cerebral metastasis
Any severe comorbidity calculated by Charlson score according to table 1
ADL \> 0 and IADL \> 1- performance status \>2 (ECOG)
peripheral neuropathy grade 2 or more
dementia, repeated falls, urinary or faecal incontinence
contra-indication to corticosteroids
contra indication to a product of this study
unwilling or unable to comply with study requirements, for personal, family, sociologic, geographic or any other reason
inability of the subject to give written informed consent
lack of liberty following legal or administrative decision
hypersensitivity to polysorbate
hypersensitivity to erlotinib or any excipients of this product
unusual hereditary disorders, as galactosemia, deficit in lactase and syndrome of malabsorption in glucose or galactose
participation in concomitant clinical trial
bronchioloalveolar or neuroendocrine or composite carcinoma
superior vena cava syndrome
Clareo Health | Elderly Dependent Patients With Non Small Cell Lung Cancer (NSCLC)
